Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vinorelbine Tartrate

FDA-approved product (injectable, injection), marketed as Navelbine, Vinorelbine Tartrate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Vinorelbine Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vinorelbine Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vinorelbine Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

    NCT07001618 · start 2025-11-17

    Registered record
    Registry ID
    NCT07001618
    Conditions
    NSCLC (Advanced Non-small Cell Lung Cancer)
    Interventions
    MaaT033 capsule; Cemiplimab; Cisplatin; Carboplatine; Pemetrexed (Alimta); Bevacizumab; Paclitaxel; gemcitabine; Docetaxel; Vinorelbine i.v. 25 mg/m²; Vinorelbine oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-17
    Completion
    2032-09
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Advanced Non-small Cell Lung Cancer)
    InterventionMaaT033 capsule; Cemiplimab; Cisplatin; Carboplatine +7 more
    PhasePhase 2
    Registry statusRecruiting

  • Optimal Application Timing of ADC Drugs for Advanced Breast Cancer

    NCT07657130 · start 2025-07-01

    Registered record
    Registry ID
    NCT07657130
    Conditions
    Breast Cancer Females
    Interventions
    Antibody drug conjugate; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-01
    Completion
    2026-12-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Females
    InterventionAntibody drug conjugate; Chemotherapy
    PhasePhase 2
    Registry statusRecruiting

  • FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

    NCT06519370 · start 2024-08-09

    Registered record
    Registry ID
    NCT06519370
    Conditions
    Triple Negative Breast Cancer
    Interventions
    FDA018-ADC; Eribulin; Capecitabine; Gemcitabine; Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-08-09
    Completion
    2027-06-20
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionFDA018-ADC; Eribulin; Capecitabine; Gemcitabine +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

    NCT07371910 · start 2024-06-12

    Registered record
    Registry ID
    NCT07371910
    Conditions
    Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer
    Interventions
    Chemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-06-12
    Completion
    2031-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer
    InterventionChemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC Regimen
    PhasePhase 3
    Registry statusActive not recruiting

  • JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

    NCT06079983 · start 2023-12-01

    Registered record
    Registry ID
    NCT06079983
    Conditions
    Breast Cancer
    Interventions
    JSKN003; Capecitabine tablets; Gemcitabine hydrochloride for injection; Vinorelbine tartrate injection; Paclitaxel for injection (albumin-bound type); Docetaxel injection; Eribulin mesylate injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-01
    Completion
    2029-03-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionJSKN003; Capecitabine tablets; Gemcitabine hydrochloride for injection; Vinorelbine tartrate injection +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

    NCT06143553 · start 2023-09-25

    Registered record
    Registry ID
    NCT06143553
    Conditions
    Metastatic Breast Cancer (MBC)
    Interventions
    Paclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection; Capecitabine Tablets; Gemcitabine Hydrochloride for Injection; Vinorelbine Tartrate Injection; Paclitaxel (albumin-bound)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-09-25
    Completion
    2025-12
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer (MBC)
    InterventionPaclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection; Capecitabine Tablets; Gemcitabine Hydrochloride for Injection +2 more
    PhasePhase 3
    Registry statusUnknown

  • Thero2-01S22 in HER2-positive Breast Cancer

    NCT05698186 · start 2023-05-15

    Registered record
    Registry ID
    NCT05698186
    Conditions
    HER2-positive Breast Cancer
    Interventions
    Thero2-01S22; Placebo; Thero2-01S22; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2023-05-15
    Completion
    2027-05-15
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer
    InterventionThero2-01S22; Placebo; Thero2-01S22; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

    NCT06310915 · start 2023-03-17

    Registered record
    Registry ID
    NCT06310915
    Conditions
    Non-small Cell Lung Cancer Stage IIIB/IV
    Interventions
    Navelbine oral,Pembrolizumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-03-17
    Completion
    2025-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Stage IIIB/IV
    InterventionNavelbine oral,Pembrolizumab
    PhaseNot recorded
    Registry statusUnknown

  • Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

    NCT05583188 · start 2023-02-01

    Registered record
    Registry ID
    NCT05583188
    Conditions
    NSCLC
    Interventions
    Aliya Pulsed Electric Fields (PEF) ablation; Nivolumab plus Platinum Doublet Chemotherapy; Standard of care neoadjuvant therapy; Surgical Resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-02-01
    Completion
    2024-03-18
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionAliya Pulsed Electric Fields (PEF) ablation; Nivolumab plus Platinum Doublet Chemotherapy; Standard of care neoadjuvant therapy; Surgical Resection
    PhasePhase 4
    Registry statusTerminated

  • Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

    NCT05603013 · start 2022-10-30

    Registered record
    Registry ID
    NCT05603013
    Conditions
    Carcinoma, Non-Small-Cell Lung; Carcinoma Breast
    Interventions
    Vinorelbine; Radiotherapy; PD-1/PD-L1 inhibitor; GM-CSF; IL-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-10-30
    Completion
    2024-10-17
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Carcinoma Breast
    InterventionVinorelbine; Radiotherapy; PD-1/PD-L1 inhibitor; GM-CSF +1 more
    PhasePhase 2
    Registry statusUnknown

  • Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

    NCT05063786 · start 2021-09-14

    Registered record
    Registry ID
    NCT05063786
    Conditions
    Advanced Breast Cancer
    Interventions
    Trastuzumab; Alpelisib; Fulvestrant; Vinorelbine; Capecitabine; Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-09-14
    Completion
    2026-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionTrastuzumab; Alpelisib; Fulvestrant; Vinorelbine +2 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

    NCT04605575 · start 2020-05-22

    Registered record
    Registry ID
    NCT04605575
    Conditions
    Breast Cancer; Pyrotinib; Breast Diseases; Vinorelbine; HER2-positive Breast Cancer
    Interventions
    Pyrotinib 320mg + Vinorelbine; Pyrotinib 400mg + Vinorelbine; Pyrotinib plus Vinorelbine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-05-22
    Completion
    2023-12-01
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Pyrotinib; Breast Diseases; Vinorelbine +1 more
    InterventionPyrotinib 320mg + Vinorelbine; Pyrotinib 400mg + Vinorelbine; Pyrotinib plus Vinorelbine
    PhasePhase 2
    Registry statusUnknown

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

    NCT03656094 · start 2018-11-01

    Registered record
    Registry ID
    NCT03656094
    Conditions
    Non-small Cell Lung Cancer Metastatic
    Interventions
    Pembrolizumab plus chemotherapy; Placebo plus chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-11-01
    Completion
    2021-11-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic
    InterventionPembrolizumab plus chemotherapy; Placebo plus chemotherapy
    PhasePhase 2
    Registry statusUnknown

  • Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

    NCT03393741 · start 2018-01-29

    Registered record
    Registry ID
    NCT03393741
    Conditions
    Breast Cancer; Breast Neoplasms
    Interventions
    Taxane; Vinorelbine; Ixabepilone; Eribulin; Chemotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-01-29
    Completion
    2024-02-11
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Neoplasms
    InterventionTaxane; Vinorelbine; Ixabepilone; Eribulin +1 more
    PhaseNot recorded
    Registry statusTerminated